The article discusses the potential of organoids in personalized medicine and regenerative therapies. Organoids, derived from an individual’s cells, offer a way to tailor treatments to patient needs by screening compounds and understanding patient-specific responses to drugs. Researchers, like Mingxia Gu at Cincinnati Children’s, are utilizing organoids to study various diseases and test potential treatments. By joining the CuSTOM initiative, researchers gain access to a community focused on organoid research, enabling collaboration and knowledge exchange. Organoids also hold promise for regenerative medicine, where patient-derived organoids could help repair damaged tissues after transplantation. The ultimate goal of initiatives like CuSTOM is to translate lab-made discoveries into clinical applications rapidly, bringing personalized therapies to patients.